Amivantamab
-
RYBREVANT® (amivantamab-vmjw) Demonstrates Promising and Durable Long-Term Responses in Difficult-to-Treat Colorectal Cancer
Johnson & Johnson’s amivantamab combined with chemotherapy shows promising results in metastatic colorectal cancer. The bispecific antibody, targeting EGFR and MET, achieved a 51% overall response rate in RAS/BRAF wild-type patients. Longer-term data indicate sustained efficacy, with over 70% response in the first-line setting and durable responses exceeding two years. The combination also demonstrated activity in patients with liver metastases, with a 57% ORR. The safety profile was consistent with prior studies, with low discontinuation rates.
-
Amivantamab Subcutaneous Formulation Shows 45% ORR in Recurrent/Metastatic Head and Neck Cancer
Johnson & Johnson presented promising Phase 1b/2 OrigAMI-4 data at ESMO 2025 on subcutaneous amivantamab for recurrent/metastatic HPV-unrelated head and neck squamous cell carcinoma (R/M HNSCC) after checkpoint inhibitor and platinum therapy failure. The study showed a 45% overall response rate and tumor shrinkage in 82% of patients, surpassing current therapy benchmarks. SC delivery allows for rapid injection, reducing clinic time. The ongoing Phase 3 OrigAMI-5 study will evaluate amivantamab with pembrolizumab and carboplatin as a first-line treatment.
